Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-EVG321
- Development stage
- Unknown
- Lead developer
- Evergreen Theragnostics
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
177Lu-EVG321 is a novel radiopharmaceutical therapy under development for the treatment of small cell lung cancer. It consists of a peptide ligand that targets the cholecystokinin 2 receptor (CCK2R), which is highly expressed on tumor cells in small cell lung cancer and potentially other solid tumors. The drug delivers lutetium-177, a beta-emitting radioisotope, directly to CCK2R-expressing tumor cells, enabling targeted ionizing radiation to ablate malignant tissue while sparing surrounding healthy tissue. This approach leverages the precision of radioligand therapy to improve outcomes in aggressive cancers with limited treatment options. The drug was originally developed at Innsbruck Medical University and is being advanced clinically by Evergreen Theragnostics[1][2][3][4][5][6].
- Other names
- LNTH-2503LNTH2503LNTH 2503EVG-321EVG321EVG 321
02
Targets
CCK2R (Cholecystokinin 2 Receptor)
Beyond the preview
Go deeper on 177Lu-EVG321.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-EVG321.